Pfizer Ireland Pharmaceuticals v Eli Lilly and Company

Link copied
Case Copied 20 min read

IN THE COURT OF APPEAL OF NEW ZEALAND

CA8/05

BETWEENPFIZER IRELAND PHARMACEUTICALS


First Appellant

ANDPFIZER NEW ZEALAND LIMITED


Second Appellant

ANDELI LILLY AND COMPANY


First Respondent

ANDELI LILLY AND COMPANY (NEW ZEALAND) LIMITED


Second Respondent

Hearing:5 August 2005

Court:Anderson P, William Young, Chambers, O'Regan and Robertson JJ

Counsel:D Shavin QC and A H Brown QC for Appellants


R J Katz QC, J L Land and S Wheeldon for Respondents

Judgment:8 December 2005 

JUDGMENT OF THE COURT

AThe appeal against the High Court judgment delivered on 3 December 2004 and the application for leave to appeal against the High Court judgment delivered on 21 November 2003 are dismissed.

BThe cross-appeal against the High Court judgment delivered on 3 December 2004 is dismissed.

CThe appellants are to pay the respondents costs of $10,000 together with usual disbursements.

DThere is a certificate for one extra counsel.

REASONS

(Given by William Young J)

Table of Contents

Para No

Introduction   [1]

THE TRADITIONAL APPROACH TO THE PLEADINGS REQUIRED OF A              [5]

patentee in revocation proceedings  
The Ancare case  [14]

THE RELEVANT INTERLOCUTORY JUDGMENTS OF POTTER J

The 2003 judgment  [19]
         The 2004 judgment[22]
The issues in this Court  [27]
Does Ancare state the law correctly?  [29]

Should we grant leave to appeal against the 2003  [35]
judgment?  
Should we allow the appeal against the 2004 judgment?            [40]
Should we allow the cross-appeal?  [44]
Result  [47]

Introduction

[1]       We are required to deal with pleading points which arise in patent litigation between the appellants (“Pfizer”) and the respondents (“Eli Lilly”).  Pfizer alleges that Eli Lilly has contravened patents associated with Viagra.  Eli Lilly denies infringement but, by way of counterclaim, asserts that the Pfizer patents are invalid on the grounds set out in accompanying (and subsequently amended) particulars of objection to validity.  In issue is the extent to which Pfizer must respond to the now amended particulars of objection.

[2]       In judgments delivered on 21 November 2003 and 3 December 2004, Potter J required Pfizer to plead in detail to what are now amended particulars of objection. In her 21 November 2003 judgment, Potter J applied the decision of this Court in Ancare New Zealand Limited v Ciba Geigy New Zealand Ltd (1997) 11 PRNZ 398.

[3]       An appeal by Pfizer, confined to the 3 December 2004 judgment and a cross‑appeal by Eli Lilly against the same judgment were listed before a bench of three Judges on 22 June 2005.  It soon became apparent that the appeal was, in substantial part, a challenge to the prior decision of this Court in Ancare.  Consequently the hearing was adjourned and argued before a full Court.  In the meantime, Pfizer applied for leave to appeal out of time against the 21 November 2003 judgment.  We heard the appeal and cross-appeal in relation to the 3 December 2004 judgment and the application for leave to appeal at the same time and all are addressed in this judgment.

[4]       We note that Pfizer and Eli Lilly are involved (or…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Eli Lilly and Company and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] NZCA 311
Decision Date

CaseChat Overview and Summary

In the Court of Appeal of New Zealand, Pfizer Ireland Pharmaceuticals and Pfizer New Zealand Limited (collectively, "Pfizer") appealed against judgments delivered by Potter J on 21 November 2003 and 3 December 2004, while Eli Lilly and Company and Eli Lilly and Company (New Zealand) Limited (collectively, "Eli Lilly") cross-appealed against the latter judgment. The case revolved around Pfizer's allegations of patent infringement by Eli Lilly concerning Viagra and Eli Lilly's counterclaim that the Pfizer patents were invalid. The central issue was the extent to which Pfizer had to respond to Eli Lilly's particulars of objection in the revocation proceedings. The Court of Appeal found that the earlier decision in Ancare New Zealand Limited v Ciba Geigy New Zealand Ltd did not correctly state the law, as it required patentees to respond in detail to particulars of objection, contrary to the traditional approach and the scheme of the applicable rules. However, the Court dismissed Pfizer's appeal against the 2004 judgment and the cross-appeal, as the 2003 judgment was beyond challenge and the 2004 judgment implemented the 2003 judgment. The Court also dismissed Pfizer's application for leave to appeal out of time against the 2003 judgment, as allowing it would cause significant prejudice to Eli Lilly.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established